Breast Cancer

, Volume 11, Issue 1, pp 86–91 | Cite as

Techniques for the neurological examination of taxane-induced neuropathy

  • Shozo Ohsumi
  • Yoshihide Sunada
Review Article


Taxanes are considered to be the key drugs in the treatment of breast cancer. Although physicians who treat patients with breast cancer have rarely seen patients with neuropathy as an adverse effect of treatment before the advent of taxanes, patients with breast cancer who are treated with taxanes frequent-ly exhibit peripheral neuropathy. As peripheral neuropathy often causes deterioration of the quality of life of patients, it is very important to precisely assess the extent of peripheral neuropathy at an early stage. Clinical oncologists should be familiar with the techniques of neurological examination. In this article we describe the basic techniques for the neurological examination of patients with tax-ane-induced peripheral neuropathy. In the hope of facilitating the precise evaluation of taxane-induced peripheral neuropathy, the items of neurological examinations in this article are described with reference to the physician neuroexamination form (PNEF) designed by BioNumerik Pharmaceuticals Inc.

Key words

Neurotoxicity Taxane Neurological examination 



Physician Neuroexamination Form


Comprehensive Support Project for Oncological Research of Breast Cancer


National Surgical Adjuvant Study of Breast Cancer


Health Outcome Research


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer.J Natl Cancer Inst 83:1797–1805, 1991.PubMedCrossRefGoogle Scholar
  2. 2).
    Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.J Clin Oncol 11:1943–1951, 1993.PubMedGoogle Scholar
  3. 3).
    Chan S, Friedrichs K, Noel D, Printer T, Belle SV, Vorobiof D, Duarte R, Gil MG, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha RG, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.J Clin Oncol 17:2341–2354, 1999.PubMedGoogle Scholar
  4. 4).
    Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol 21:976–983, 2003.PubMedCrossRefGoogle Scholar
  5. 5).
    Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N: Paclitaxel following doxoru-bicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer.Proc Am Soc Clin Oncol 22:4 (Abstract 12), 2003.Google Scholar
  6. 6).
    Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Foraander T, Blitz S, Gazel S, Loret C, Riva A: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluo-rouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study.Proc Am Soc Clin Oncol 21:36a (Abstract 141), 2002.Google Scholar
  7. 7).
    van den Bent MJ, van Raaij-van den Aarssen VJM, Verweij J Doom PAV, Sillevis Smitt PAE: Progression of paclitaxel induced neuropathy following discontinuation of treatment.Muscle Nerve 20:750–752, 1997.PubMedCrossRefGoogle Scholar
  8. 8).
    DeMyer WE: Technique of the neurological examination: A programmed text. Fourth edition, McGraw-Hill Inc, New York, 1994.Google Scholar
  9. 9).
    Sugiura K: Illustrated guide to the neurologic examination. Ishiyaku Publishers Inc, Tokyo, 1993 (in Japanese).Google Scholar
  10. 10).
    Hilkens PHE, and van den Bent MJ: Chemotherapy-induced peripheral neuropathy.J Periper Nerv Syst 2:350–361, 1997.Google Scholar
  11. 11).
    Mendell JR, Kissel JT, Cornblath DR: Diagnosis and management of peripheral nerve disorders. Oxford University Press Inc, New York, 2001.Google Scholar
  12. 12).
    Iwata M: Textbook of symptomatology in neurology. Igaku-shoin, Tokyo, 1994 (in Japanese).Google Scholar

Copyright information

© The Japanese Breast Cancer Society 2004

Authors and Affiliations

  1. 1.Department of SurgeryNational Shikoku Cancer CenterMatsuyama, EhimeJapan
  2. 2.Department of NeurologyKawasaki Medical UniversityJapan

Personalised recommendations